Alvotech ( (ALVO) ) has issued an announcement.
On March 18, 2025, Alvotech announced that the FDA has accepted the Biologics License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®. This milestone is significant for Alvotech as it advances its mission to provide affordable biologic medicines, potentially impacting the treatment of osteoporosis and bone-related diseases in the U.S. market. The acceptance of AVT03’s application marks a critical step in Alvotech’s collaboration with Dr. Reddy’s Laboratories, which is responsible for the registration and commercialization of AVT03 in the U.S.
More about Alvotech
Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines. It aims to be a leader in the biosimilar space by offering high-quality, cost-effective products and services. The company has a pipeline of biosimilar candidates targeting various conditions, including autoimmune disorders and osteoporosis, and has formed strategic partnerships to expand its global reach.
YTD Price Performance: -14.06%
Average Trading Volume: 165,680
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.41B
For a thorough assessment of ALVO stock, go to TipRanks’ Stock Analysis page.